Assembly Biosciences Net Income Over Time
| ASMB Stock | USD 29.59 0.25 0.85% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Assembly Biosciences Performance and Assembly Biosciences Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Assembly Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (4.60) | Revenue Per Share | Quarterly Revenue Growth 0.576 | Return On Assets | Return On Equity |
Assembly Biosciences's market price often diverges from its book value, the accounting figure shown on Assembly's balance sheet. Smart investors calculate Assembly Biosciences' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Assembly Biosciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Assembly Biosciences' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assembly Biosciences represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Assembly Biosciences and related stocks such as Zura Bio Limited, Foghorn Therapeutics, and Immuneering Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZURA | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | (25.7 M) | (60.4 M) | (52.4 M) | (47.2 M) | (49.5 M) |
| FHTX | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (26.3 M) | (51.1 M) | (68.8 M) | (101.3 M) | (108.9 M) | (98.4 M) | (86.6 M) | (78 M) | (81.9 M) |
| IMRX | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (17 M) | (33.5 M) | (50.5 M) | (53.5 M) | (61 M) | (54.9 M) | (57.7 M) |
| SGMT | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (14.3 M) | (11.4 M) | (24.4 M) | (30.5 M) | (27.9 M) | (45.6 M) | (41 M) | (43.1 M) |
| ENTA | 7.9 M | 21.4 M | 9.6 M | 34.4 M | 79 M | 21.7 M | 17.7 M | 72 M | 46.4 M | (36.2 M) | (79 M) | (121.8 M) | (133.8 M) | (116 M) | (81.9 M) | (73.7 M) | (70 M) |
| AARD | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (7.2 M) | (20.6 M) | (18.5 M) | (19.5 M) |
| NAUT | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | 626.6 M | (9.6 M) | (15.6 M) | (50.3 M) | (57.9 M) | (63.7 M) | (70.8 M) | (63.7 M) | (60.5 M) |
| ARCT | (3.9 M) | (3.9 M) | (1.6 M) | (10.5 M) | (32.8 M) | (19.4 M) | (24.6 M) | (10.9 M) | (21.8 M) | (26 M) | (72.1 M) | (203.7 M) | 9.3 M | (29.7 M) | (80.9 M) | (72.8 M) | (69.2 M) |
| PYXS | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (12.8 M) | (76 M) | (118 M) | (73.8 M) | (77.3 M) | (69.6 M) | (73.1 M) |
| TNYA | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (25.8 M) | (38.4 M) | (69.7 M) | (123.7 M) | (124.1 M) | (111.1 M) | (100 M) | (105 M) |
Assembly Biosciences and related stocks such as Zura Bio Limited, Foghorn Therapeutics, and Immuneering Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Assembly Biosciences financial statement analysis. It represents the amount of money remaining after all of Assembly Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Assembly Biosciences | ASMB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | Two Tower Place, |
| Exchange | NASDAQ Exchange |
USD 29.59
Check out Assembly Biosciences Performance and Assembly Biosciences Correlation. For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Assembly Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.